Serge P. Marinkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Serge P. Marinkovic has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Lisa M. Gillen
Department of Urology, Detroit Medical Center, Detroit, Michigan
4 shared publicationsLisa M Gillen
Department of Urology, Southern Illinois School of Medicine, Springfield, IL, USA
3 shared publicationsSerge P. Marinkovic
Department of Urology, Detroit Medical Center, Detroit, Michigan
3 shared publicationsStuart L Stanton
Female Reconstructive Surgery, St George’s School of Medicine, London, UK
3 shared publications- Christina M. Marinkovic
Department of Urology, Detroit Medical Center, Harper/Hutzel Hospital, Detroit, MI, 48202, USA
2 shared publications C. Frey
Penn State Geisinger Health System
1 shared publication
Latest Publications
- 12 September 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (8) , 2233-2241
Improving clinical outcomes with lower motor voltage (≤3 V) during stage 1 sacral neuromodulation for interstitial cystitis or bladder pain syndrome
Aims: We desire to evaluate whether utilization of ≤3 V (new experimental approach) vs the traditional four or more volts for lead motor response during stage 1 sacral neuromodulation may impart an improvement in voiding and pain parameters.Methods: An observational, retrospective, double cohort review was conducted of 179 female patients who experienced medically recalcitrant interstitial cystitis (IC) or bladder pain syndrome (BPS) between January 2002 and January 2013. Group A included 105 women with a motor response of ≤3 V; group B was comprised of 65 women with a motor response at ≥4 V for medically recalcitrant IC or BPS. Patients completed a 3‐day pre‐ and postoperative voiding diary, visual analog pain (VAP) scale, pain urgency frequency (PUF), and Patient Global Impression of Improvement (PGI‐I) questionnaire.Results: The mean (standard deviation) follow‐up in months was 120.1 ± 33.3 in group A and 116.3 ± 29.2 in group B (P < .45). A successful conversion from stage 1 to stage 2 showed statistically significant improvement for group A compared with group B (95.4% vs 73.8% conversion rate; P < .001). The success rate also favored group A, with 87.6% success compared with 66.2% for group B (P < .002). Group A mean postoperative VAP scores improved over group B with 3.3 ± 1.2 compared with 5.0 ± 0.8 (P < .001). Group A mean postoperative PUF scores were 10.2 ± 2.7 and group B 14.7 ± 3.5, (P < .001).Conclusions: In the ≤3 V patient cohort, a compelling, significant statistical improvement was noted in most clinical voiding parameters, including the VAP, PGI‐I, and performance questionnaires.
- 12 September 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (8) , 2233-2241
Improving clinical outcomes with lower motor voltage (≤3 V) during stage 1 sacral neuromodulation for interstitial cystitis or bladder pain syndrome
Aims: We desire to evaluate whether utilization of ≤3 V (new experimental approach) vs the traditional four or more volts for lead motor response during stage 1 sacral neuromodulation may impart an improvement in voiding and pain parameters.Methods: An observational, retrospective, double cohort review was conducted of 179 female patients who experienced medically recalcitrant interstitial cystitis (IC) or bladder pain syndrome (BPS) between January 2002 and January 2013. Group A included 105 women with a motor response of ≤3 V; group B was comprised of 65 women with a motor response at ≥4 V for medically recalcitrant IC or BPS. Patients completed a 3‐day pre‐ and postoperative voiding diary, visual analog pain (VAP) scale, pain urgency frequency (PUF), and Patient Global Impression of Improvement (PGI‐I) questionnaire.Results: The mean (standard deviation) follow‐up in months was 120.1 ± 33.3 in group A and 116.3 ± 29.2 in group B (P < .45). A successful conversion from stage 1 to stage 2 showed statistically significant improvement for group A compared with group B (95.4% vs 73.8% conversion rate; P < .001). The success rate also favored group A, with 87.6% success compared with 66.2% for group B (P < .002). Group A mean postoperative VAP scores improved over group B with 3.3 ± 1.2 compared with 5.0 ± 0.8 (P < .001). Group A mean postoperative PUF scores were 10.2 ± 2.7 and group B 14.7 ± 3.5, (P < .001).Conclusions: In the ≤3 V patient cohort, a compelling, significant statistical improvement was noted in most clinical voiding parameters, including the VAP, PGI‐I, and performance questionnaires.
- Open Access
- 1 January 2019
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 11
New technologies in the management of overactive bladder: current research and future prospects
Overactive bladder is characterized by frequency, urgency (wet or dry) and nocturia. These troublesome symptoms incur both a physiologic and economic cost, expected to be in excess of US$82 billion in the USA and Europe by the year 2020. Second-tier medicinal oral therapies for overactive bladder abound, but the failure rate or discontinuation at 1 year exceeds 50%. Tertiary-tier therapies involve surgical alternatives including neuromodulation of sacral nerve 3 (S3) or the posterior tibial nerve as a means to manipulate and ameliorate the above-described voiding symptoms. Sacral neuromodulation has been studied for more than 20 years, but newer, smaller, rechargeable implantable devices are in the forefront of current investigation. Hopes are that modifications to the device will eventually be possible at the patient’s home, rather than the physician’s office, with close urological/gynecologic supervision and guidance. Another means of surgical intervention for overactive bladder includes the use of a cystoscopy-guided radiofrequency probe by which energy disrupts the bladder floor neural voiding plexi. Stem cell therapy is also being evaluated for overactive bladder but is in the early stages of development.
- 1 January 2019
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 11
Open AccessNew technologies in the management of overactive bladder: current research and future prospects
Overactive bladder is characterized by frequency, urgency (wet or dry) and nocturia. These troublesome symptoms incur both a physiologic and economic cost, expected to be in excess of US$82 billion in the USA and Europe by the year 2020. Second-tier medicinal oral therapies for overactive bladder abound, but the failure rate or discontinuation at 1 year exceeds 50%. Tertiary-tier therapies involve surgical alternatives including neuromodulation of sacral nerve 3 (S3) or the posterior tibial nerve as a means to manipulate and ameliorate the above-described voiding symptoms. Sacral neuromodulation has been studied for more than 20 years, but newer, smaller, rechargeable implantable devices are in the forefront of current investigation. Hopes are that modifications to the device will eventually be possible at the patient’s home, rather than the physician’s office, with close urological/gynecologic supervision and guidance. Another means of surgical intervention for overactive bladder includes the use of a cystoscopy-guided radiofrequency probe by which energy disrupts the bladder floor neural voiding plexi. Stem cell therapy is also being evaluated for overactive bladder but is in the early stages of development.
- 10 April 2018
- Published by Wiley in BJU International
- Vol. 122 (3) , 472-479
Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1–9 V) during Stage 1 sacral neuromodulation
Objective: To assess whether the utilisation of a motor response of 4 V in patients with overactive bladder ( OAB ) or urinary retention symptoms. Patients and Methods: An observational, retrospective, double cohort review was conducted of 339 female patients who had experienced medically recalcitrant OAB or urinary retention symptoms. Between September 2001 and September 2014, both cohorts underwent successful Stage 1 to Stage 2 SNM placement. Group A, included 174 women with a motor response at ≤3 V; and Group B, evaluated 110 women with a motor response at ≥4 V for medically recalcitrant OAB . Group C, compared 33 women with a motor response at ≤3 V; and Group D, documented 22 women with a motor response at ≥4 V for non‐obstructive urinary retention. Patients completed 3‐day voiding diaries, the Urogenital Distress Inventory‐6 ( UDI ‐6), Incontinence Impact Questionnaire‐7 ( IIQ ‐7), and Patient Global Impression of Improvement Questionnaire. Results: The mean ( sd ) follow‐up was 116.3 (30.3) months in Group A and 112 (34.6) months in Group B ( P < 0.354); 150.5 (20.4) months in Group C and 145.8 (17.2) months in Group D ( P < 0.38). Successful conversion of Stage 1 to Stage 2 showed statistically significant improvement for both P < 0.001). Group C had a 94% (34/36) conversion rate vs 70% (21/30) in Group D ( P < 0.017). Defined as a ≥50% reduction in frequency, urgency, urgency incontinence and nocturia, and UDI ‐6 and IIQ ‐7 scores, the success rate for Group A was 82.1% (143/174) and for Group B was 63% (69/110) ( P < 0.001). The mean battery life improved in both P < 0.001). Annual reprogramming sessions were reduced in Group A and Group C ( P < 0.001). Subset analysis of variance showed no statistical improvement in most patient outcomes when 1‐V subjects were compared to 2‐ and 3‐V cohorts. However, 32% of 1‐V patients ( P < 0.001) noted the onset of severe pelvic/perirectal pain and big toe plantar flexion movement with small increments in voltage (0.1–0.2 V) during reprogramming. Only 7% of 2‐V and 1% of 3‐V patients experienced this complication. Conclusions: Significant improvement was noted (up to 40%) in most clinical voiding parameters in the <3‐V patients for both OAB and urinary retention. While <3 V will still statistically improve patient outcomes, a voltage <2 V may elicit self‐reprogramming pain with severe bellows and plantar flexion movement, which may discourage patients from therapy adjustments. We recommend randomised, controlled trials to confirm these results.
- 10 April 2018
- Published by Wiley in BJU International
- Vol. 122 (3) , 472-479
Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1–9 V) during Stage 1 sacral neuromodulation
Objective: To assess whether the utilisation of a motor response of 4 V in patients with overactive bladder ( OAB ) or urinary retention symptoms. Patients and Methods: An observational, retrospective, double cohort review was conducted of 339 female patients who had experienced medically recalcitrant OAB or urinary retention symptoms. Between September 2001 and September 2014, both cohorts underwent successful Stage 1 to Stage 2 SNM placement. Group A, included 174 women with a motor response at ≤3 V; and Group B, evaluated 110 women with a motor response at ≥4 V for medically recalcitrant OAB . Group C, compared 33 women with a motor response at ≤3 V; and Group D, documented 22 women with a motor response at ≥4 V for non‐obstructive urinary retention. Patients completed 3‐day voiding diaries, the Urogenital Distress Inventory‐6 ( UDI ‐6), Incontinence Impact Questionnaire‐7 ( IIQ ‐7), and Patient Global Impression of Improvement Questionnaire. Results: The mean ( sd ) follow‐up was 116.3 (30.3) months in Group A and 112 (34.6) months in Group B ( P < 0.354); 150.5 (20.4) months in Group C and 145.8 (17.2) months in Group D ( P < 0.38). Successful conversion of Stage 1 to Stage 2 showed statistically significant improvement for both P < 0.001). Group C had a 94% (34/36) conversion rate vs 70% (21/30) in Group D ( P < 0.017). Defined as a ≥50% reduction in frequency, urgency, urgency incontinence and nocturia, and UDI ‐6 and IIQ ‐7 scores, the success rate for Group A was 82.1% (143/174) and for Group B was 63% (69/110) ( P < 0.001). The mean battery life improved in both P < 0.001). Annual reprogramming sessions were reduced in Group A and Group C ( P < 0.001). Subset analysis of variance showed no statistical improvement in most patient outcomes when 1‐V subjects were compared to 2‐ and 3‐V cohorts. However, 32% of 1‐V patients ( P < 0.001) noted the onset of severe pelvic/perirectal pain and big toe plantar flexion movement with small increments in voltage (0.1–0.2 V) during reprogramming. Only 7% of 2‐V and 1% of 3‐V patients experienced this complication. Conclusions: Significant improvement was noted (up to 40%) in most clinical voiding parameters in the <3‐V patients for both OAB and urinary retention. While <3 V will still statistically improve patient outcomes, a voltage <2 V may elicit self‐reprogramming pain with severe bellows and plantar flexion movement, which may discourage patients from therapy adjustments. We recommend randomised, controlled trials to confirm these results.
- 1 February 2017
- Published by SAGE Publications in Videourology™
- Vol. 31 (1)
Successful Lower Motor Voltage Provocation May Lead to Better Patient Improvement from Overactive Bladder Symptoms
Introduction: Will attainment of good bellows/plantar flexion at ≤3 volts fare better in controlling overactive bladder symptoms than at >4 volts? Methods: Between September 2001 and September 2010, we performed a retrospective cohort review of patients who underwent Stages 1 and 2 sacral neuromodulation placement for medically recalcitrant overactive bladder symptoms. All patients had pre- and postoperative overactive bladder symptom voiding diary results undergo statistical multivariable analysis. Group 1 patients had one or more tine leads placed with excellent motor provocation at ≤3 volts while Group 2 at >4 volts. Results: Mean follow-up of Group 1 (≤3 volts) was 8.43 ± 5.22 years and that of Group 2 (>3 volts)] was 9.56 ± 4.89 years. Patients with one lead with bellows and plantar flexion at ≤3 volts performed markedly better with improvements to frequency q24 hours Group 1, 18.72 ± 6.32 to 9.89 ± 3.12, compared with Group 2, 17.82 ± 5.23 to 11.88 ± 4.56, p < 0.02] urgency q24 hours Group 1 [2.87 ± 1.22 to 1.08 ± 0.68 compared with Group 2 2.77 ± 1.38 to 1.89 ± 1.02, p < 0.01], urgency incontinence Group1, 1.55 ± 1.21 to 0.70 ± 0.41 compared with Group 2, 1.48 ± 0.97 to 1.20 ± 0.51, p < 0.01 and nocturia Group 1, 3.02 ± 1.52 to 1.78 ± 0.79, Group 2, 3.33 ± 1.89 to 2.88 ± 1.46 voids per night (p < 0.02). Baseline UDI-6 scores improved from Group 1, 32.8 ± 22.1 to 6.9 ± 10.2, versus Group 2, 30.4 ± 19.6 to 8.9 ± 4.5 (p < 0.001). Similarly, IIQ-7 scores improved from Group 1, 22.1 ± 19.8 to 2.4 ± 8.2, versus Group 2, 20.6 ± 16.4 to 5.5 ± 6.3 (p < 0.02). Conclusions: Attainment of good bellows and plantar flexion at ≤3 volts with one or more leads may portend better qualitative clinical results for overactive bladder symptoms in women. No competing financial interests exist. Runtime of video: 6 mins 40 secs
- 1 February 2017
- Published by SAGE Publications in Videourology™
- Vol. 31 (1)
Successful Lower Motor Voltage Provocation May Lead to Better Patient Improvement from Overactive Bladder Symptoms
Introduction: Will attainment of good bellows/plantar flexion at ≤3 volts fare better in controlling overactive bladder symptoms than at >4 volts? Methods: Between September 2001 and September 2010, we performed a retrospective cohort review of patients who underwent Stages 1 and 2 sacral neuromodulation placement for medically recalcitrant overactive bladder symptoms. All patients had pre- and postoperative overactive bladder symptom voiding diary results undergo statistical multivariable analysis. Group 1 patients had one or more tine leads placed with excellent motor provocation at ≤3 volts while Group 2 at >4 volts. Results: Mean follow-up of Group 1 (≤3 volts) was 8.43 ± 5.22 years and that of Group 2 (>3 volts)] was 9.56 ± 4.89 years. Patients with one lead with bellows and plantar flexion at ≤3 volts performed markedly better with improvements to frequency q24 hours Group 1, 18.72 ± 6.32 to 9.89 ± 3.12, compared with Group 2, 17.82 ± 5.23 to 11.88 ± 4.56, p < 0.02] urgency q24 hours Group 1 [2.87 ± 1.22 to 1.08 ± 0.68 compared with Group 2 2.77 ± 1.38 to 1.89 ± 1.02, p < 0.01], urgency incontinence Group1, 1.55 ± 1.21 to 0.70 ± 0.41 compared with Group 2, 1.48 ± 0.97 to 1.20 ± 0.51, p < 0.01 and nocturia Group 1, 3.02 ± 1.52 to 1.78 ± 0.79, Group 2, 3.33 ± 1.89 to 2.88 ± 1.46 voids per night (p < 0.02). Baseline UDI-6 scores improved from Group 1, 32.8 ± 22.1 to 6.9 ± 10.2, versus Group 2, 30.4 ± 19.6 to 8.9 ± 4.5 (p < 0.001). Similarly, IIQ-7 scores improved from Group 1, 22.1 ± 19.8 to 2.4 ± 8.2, versus Group 2, 20.6 ± 16.4 to 5.5 ± 6.3 (p < 0.02). Conclusions: Attainment of good bellows and plantar flexion at ≤3 volts with one or more leads may portend better qualitative clinical results for overactive bladder symptoms in women. No competing financial interests exist. Runtime of video: 6 mins 40 secs
- 1 October 2016
- Published by SAGE Publications in Videourology™
- Vol. 30 (5)
Pudendal Neuromodulation for Salvage Sacral Neuromodulation
Introduction: At times, sacral neuromodulation may fail primarily or secondarily to treat overactive symptoms or nonobstructive urinary retention. Can pudendal neuromodulation be utilized to treat these patients with continued success with either disease entity? Materials and Methods: Between February 2014 and 2016, 14 patients underwent pudendal neuromodulation placement after failed stage 2 sacral neuromodulation without lead migration and could not control their symptoms as well as before. All underwent unilateral right-sided pudendal stage 1 neuromodulation for at least a 2-week trial with weekly follow-ups of their voiding diaries and straight catheterization of postvoiding residual urines. Results: Eighty-six percent of patients [12/14] had a 50% improvement with a 50% reduction of frequency, urgency, and nocturia [9/9]. Whereas 3/5 in urinary retention were able to void with a postvoid straight catheterization of Conclusion: In the short-term, pudendal neuromodulation can be utilized with good success as a surgical salvage procedure for either overactive bladder symptoms or nonobstructive urinary retention [other than diabetic cystopathy]. We feel capturing an anal wink and EMG tracing a No competing financial interests exist. Runtime of video: 6 mins 56 secs
- 1 October 2016
- Published by SAGE Publications in Videourology™
- Vol. 30 (5)
Pudendal Neuromodulation for Salvage Sacral Neuromodulation
Introduction: At times, sacral neuromodulation may fail primarily or secondarily to treat overactive symptoms or nonobstructive urinary retention. Can pudendal neuromodulation be utilized to treat these patients with continued success with either disease entity? Materials and Methods: Between February 2014 and 2016, 14 patients underwent pudendal neuromodulation placement after failed stage 2 sacral neuromodulation without lead migration and could not control their symptoms as well as before. All underwent unilateral right-sided pudendal stage 1 neuromodulation for at least a 2-week trial with weekly follow-ups of their voiding diaries and straight catheterization of postvoiding residual urines. Results: Eighty-six percent of patients [12/14] had a 50% improvement with a 50% reduction of frequency, urgency, and nocturia [9/9]. Whereas 3/5 in urinary retention were able to void with a postvoid straight catheterization of Conclusion: In the short-term, pudendal neuromodulation can be utilized with good success as a surgical salvage procedure for either overactive bladder symptoms or nonobstructive urinary retention [other than diabetic cystopathy]. We feel capturing an anal wink and EMG tracing a No competing financial interests exist. Runtime of video: 6 mins 56 secs
- Open Access
- 25 March 2016
- Published by Springer Nature in BMC Urology
- Vol. 16 (1) , 1-4
Transvaginal rectocele repair with human dermal allograft interposition and bilateral sacrospinous fixation with a minimum eight-year follow-up
Human dermal allografts have been used for over a decade for interpositional repair of rectoceles. How do dermal allografts perform with regards to success rate and complications with 8 years’ minimum follow-up? We retrospectively reviewed 41 consecutive patients undergoing dermal allograft interposition procedures between October 2001 and December 2005 (Repliform, Boston Scientific, Natick, MA, USA) for stage two, three, and four International Continence Society (ICS) symptomatic rectocele repairs with bilateral sacrospinous fixation. Failure was defined as recurrent stage two International Continence Society prolapse (Ap ≥ −1 and/or Bp ≥ −1). All questionnaires were completed 1 week before surgery and at follow-up (September 2014 through December 2014). The mean preoperative and postoperative A(p) were 0.95 ± 0.70,−1.90 ± 0.52 and B(p) 1.30 ± 0.84,−2.13 ± 0.51 (p < 0.001). With a mean follow-up of 116.5 ± 18.9 months, a success rate of 73 % (30/41) was achieved, with anatomical reduction of prolapse. For splinting and digitations, an 82 % cure rate was realized. The Pelvic Floor Distress Inventory (PFDI) pre- and post-operative results showed significant improvement (p < 0.001). There were two incisional exposures (5 %). Seventy percent of patients were secondary repairs while 30 % were primary repairs (81 % success rate, p < 0.36). One patient experienced nerve entrapment and subsequent unilateral takedown. Patient satisfaction was 77 %. Our retrospective study approaching long-term results demonstrated that symptomatic rectocele procedures with human dermal allograft interposition provide an effective anatomical and functional repair with acceptable complication rates.
- 25 March 2016
- Published by Springer Nature in BMC Urology
- Vol. 16 (1) , 1-4
Open AccessTransvaginal rectocele repair with human dermal allograft interposition and bilateral sacrospinous fixation with a minimum eight-year follow-up
Human dermal allografts have been used for over a decade for interpositional repair of rectoceles. How do dermal allografts perform with regards to success rate and complications with 8 years’ minimum follow-up? We retrospectively reviewed 41 consecutive patients undergoing dermal allograft interposition procedures between October 2001 and December 2005 (Repliform, Boston Scientific, Natick, MA, USA) for stage two, three, and four International Continence Society (ICS) symptomatic rectocele repairs with bilateral sacrospinous fixation. Failure was defined as recurrent stage two International Continence Society prolapse (Ap ≥ −1 and/or Bp ≥ −1). All questionnaires were completed 1 week before surgery and at follow-up (September 2014 through December 2014). The mean preoperative and postoperative A(p) were 0.95 ± 0.70,−1.90 ± 0.52 and B(p) 1.30 ± 0.84,−2.13 ± 0.51 (p < 0.001). With a mean follow-up of 116.5 ± 18.9 months, a success rate of 73 % (30/41) was achieved, with anatomical reduction of prolapse. For splinting and digitations, an 82 % cure rate was realized. The Pelvic Floor Distress Inventory (PFDI) pre- and post-operative results showed significant improvement (p < 0.001). There were two incisional exposures (5 %). Seventy percent of patients were secondary repairs while 30 % were primary repairs (81 % success rate, p < 0.36). One patient experienced nerve entrapment and subsequent unilateral takedown. Patient satisfaction was 77 %. Our retrospective study approaching long-term results demonstrated that symptomatic rectocele procedures with human dermal allograft interposition provide an effective anatomical and functional repair with acceptable complication rates.
- 1 August 2015
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 18 (6) , 517-521
Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up
- 1 August 2015
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 18 (6) , 517-521
Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up
- Open Access
- 18 February 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 4
Spleen injury following left extracorporeal shockwave lithotripsy (ESWL)
A splenic rupture associated with extracorporeal shockwave lithotripsy (ESWL) is exceedingly rare. We report a case of stage 3 splenic laceration, hemoperitoneum and subsequent splenic rupture following an ESWL for a left mid polar renal calculus.
- 18 February 2015
- Published by Springer Nature in BMC Urology
- Vol. 15 (1) , 4
Open AccessSpleen injury following left extracorporeal shockwave lithotripsy (ESWL)
A splenic rupture associated with extracorporeal shockwave lithotripsy (ESWL) is exceedingly rare. We report a case of stage 3 splenic laceration, hemoperitoneum and subsequent splenic rupture following an ESWL for a left mid polar renal calculus.
- 29 October 2013
- Published by Wiley in International Journal of Urology
- Vol. 21 (4) , 430-431
Sacral neuromodulation is an effective option for non-obstructive urinary retention in men with cerebral palsy
- 29 October 2013
- Published by Wiley in International Journal of Urology
- Vol. 21 (4) , 430-431
Sacral neuromodulation is an effective option for non-obstructive urinary retention in men with cerebral palsy